Fulcrum Therapeutics has acquired all worldwide development and commercialization rights of investigational drug losmapimod from GlaxoSmithKline (GSK). Under an exclusive worldwide license agreement, Fulcrum will develop and commercialize losmapimod, a potential disease-modifying therapy for facioscapulohumeral […]
SMi reports: The upcoming Pain Therapeutics conference, taking place on the 13th and 14th May 2019, will gather expert speakers to address several industry-led themes. SMi’s Pain Therapeutics conference is returning to London for its […]
AstraZeneca and MSD have received a positive opinion for Lynparza (olaparib) as a first-line maintenance treatment of BRCA-mutated advanced ovarian cancer. The decision was made by the European Medicines Agency’s Committee for Medicinal Products for […]
Hear Edmond Israelski (Abbott Laboratories), Lin Li (Eli Lilly) and Diane Doughty (MedImmune) discuss improving patient centricity through digital health at the Prefilled Syringes West Coast Conference, taking place on June 3rd to June 4th […]
Forge Therapeutics has partnered with Basilea Pharmaceutica for the discovery, development and commercialisation of new antibiotics. The alliance will use Forge’s metalloenzyme chemistry platform Blacksmith to develop potent inhibitors targeting two unexploited targets. These areas […]